MEP47208A - 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors - Google Patents
4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitorsInfo
- Publication number
- MEP47208A MEP47208A MEP-472/08A MEP47208A MEP47208A ME P47208 A MEP47208 A ME P47208A ME P47208 A MEP47208 A ME P47208A ME P47208 A MEP47208 A ME P47208A
- Authority
- ME
- Montenegro
- Prior art keywords
- quinazolines
- quinolines
- phenylamino
- tyrosine kinase
- kinase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Abstract
Ovaj pronalazak se odnosi na biciklične heterociklične grupe opšte formule u kojoj su R³, Rb, Rc, Rd i X definisani kao u zahttjevu 1, njihovi tautomeri, stereoizomeri, smješe i soli, posebno njihovi fiziološki prihvatljive soli sa neorganskim ili organskim kisjelinama koje imaju dragocjene farmakološke osobine, posebno inhibitorni efekat na prenos signala posredovan tirozni kinazama, za njihovu primjenu u liječenju oboljenja, posebno tumora, kao i benigne hiperplazije prostate (BPH), oboljenja pluća i respiratornog trakta, i njihovi preparati.The present invention relates to bicyclic heterocyclic groups of general formula in which R³, Rb, Rc, Rd and X are as defined in claim 1, their tautomers, stereoisomers, mixtures and salts, in particular their physiologically acceptable salts with inorganic or organic acids having valuable pharmacological properties, in particular an inhibitory effect on signaling mediated by tyrosine kinases, for their use in the treatment of diseases, especially tumors, as well as benign prostatic hyperplasia (BPH), lung and respiratory tract diseases, and their preparations.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10214412A DE10214412A1 (en) | 2002-03-30 | 2002-03-30 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and process for their preparation |
DE2002131711 DE10231711A1 (en) | 2002-07-13 | 2002-07-13 | New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors or respiratory or gastrointestinal diseases |
PCT/EP2003/003062 WO2003082290A1 (en) | 2002-03-30 | 2003-03-25 | 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MEP47208A true MEP47208A (en) | 2011-02-10 |
Family
ID=28676040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-472/08A MEP47208A (en) | 2002-03-30 | 2003-03-25 | 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1492536B1 (en) |
JP (1) | JP4776882B2 (en) |
KR (1) | KR101064530B1 (en) |
CN (1) | CN1642552B (en) |
AR (1) | AR039187A1 (en) |
AT (1) | ATE557008T1 (en) |
AU (1) | AU2003226705B2 (en) |
BR (1) | BR0308902A (en) |
CA (1) | CA2476008C (en) |
EA (2) | EA009300B1 (en) |
HK (1) | HK1079095A1 (en) |
HR (1) | HRP20040898A2 (en) |
IL (1) | IL164167A0 (en) |
ME (1) | MEP47208A (en) |
MX (1) | MXPA04009536A (en) |
MY (1) | MY127771A (en) |
NO (1) | NO329271B1 (en) |
NZ (1) | NZ536114A (en) |
PE (1) | PE20040169A1 (en) |
PL (1) | PL371188A1 (en) |
RS (1) | RS85404A (en) |
TW (2) | TW201024269A (en) |
UY (1) | UY27737A1 (en) |
WO (1) | WO2003082290A1 (en) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE04748B1 (en) | 1999-06-21 | 2006-12-15 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocyclic compounds, drugs containing these compounds, their use and methods for their preparation |
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
EP2277867B1 (en) * | 2002-07-15 | 2012-12-05 | Symphony Evolution, Inc. | Compounds, pharmaceutical compositions thereof and their use in treating cancer |
CA2527017A1 (en) * | 2003-05-27 | 2004-12-09 | Pfizer Products Inc. | Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
WO2006074147A2 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
DE10334226A1 (en) * | 2003-07-28 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
EP1660479A1 (en) * | 2003-07-29 | 2006-05-31 | Astrazeneca AB | Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors |
GB0317665D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
CN1882573A (en) * | 2003-09-16 | 2006-12-20 | 阿斯利康(瑞典)有限公司 | Quinazoline derivatives as tyrosine kinase inhibitors |
WO2005026150A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
CN1882570B (en) * | 2003-09-19 | 2010-12-08 | 阿斯利康(瑞典)有限公司 | Quinazoline derivatives |
ES2279441T3 (en) * | 2003-09-19 | 2007-08-16 | Astrazeneca Ab | DERIVATIVES OF QUINAZOLINA. |
GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
US7456189B2 (en) | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
DE10345875A1 (en) * | 2003-09-30 | 2005-04-21 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods of preparation |
DE10350717A1 (en) * | 2003-10-30 | 2005-06-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
MXPA06007017A (en) | 2003-12-18 | 2006-08-31 | Janssen Pharmaceutica Nv | Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents. |
WO2005058318A1 (en) | 2003-12-18 | 2005-06-30 | Janssen Pharmaceutica N.V. | 3-cyano-quinoline derivatives with antiproliferative activity |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
NI200700147A (en) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | QUINAZOLINE DERIVATIVES KINE INHIBITORS TARGETING MULTIP |
ATE501148T1 (en) | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTI-TUMOR AGENTS |
PE20060777A1 (en) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
MX2007009265A (en) * | 2005-02-04 | 2007-09-07 | Boehringer Ingelheim Int | Use of tyrosine kinase inhibitors for the treatment of chronic rhinosinusitis. |
WO2006081741A1 (en) * | 2005-02-05 | 2006-08-10 | Piaoyang Sun | Quinazoline compounds or their medical salts and preparation and medical usage thereof |
TW200640904A (en) * | 2005-02-26 | 2006-12-01 | Astrazeneca Ab | Quinazoline derivatives |
EP1919900A2 (en) * | 2005-08-22 | 2008-05-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof |
ATE488513T1 (en) | 2005-09-20 | 2010-12-15 | Astrazeneca Ab | 4-(1H-INDAZOLE-5-YLAMINO)QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER |
WO2007054550A1 (en) | 2005-11-11 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
BRPI0619603A2 (en) * | 2005-12-12 | 2011-10-11 | Boehringer Ingelheim Int | bicyclic heterocycles, physiologically compatible salts, medicaments containing such compounds, as well as use and processes for the production of bicyclic heterocycles |
WO2007101782A1 (en) * | 2006-03-09 | 2007-09-13 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and process for preparing them |
WO2008006884A2 (en) | 2006-07-13 | 2008-01-17 | Janssen Pharmaceutica N.V. | Mtki quinazoline derivatives |
WO2008033749A2 (en) * | 2006-09-11 | 2008-03-20 | Curis, Inc. | Quinazoline based egfr inhibitors containing a zinc binding moiety |
SG174772A1 (en) * | 2006-09-11 | 2011-10-28 | Curis Inc | Multi-functional small molecules as anti-proliferative agents |
DK2068880T3 (en) | 2006-09-18 | 2012-07-23 | Boehringer Ingelheim Int | Method of treating cancer harboring EGFR mutations |
EP1921070A1 (en) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation |
EP1956010A1 (en) * | 2007-02-06 | 2008-08-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclical heterocycles, medicines containing these compounds, their application and method for their production |
WO2008095847A1 (en) * | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
DK2185562T3 (en) | 2007-07-27 | 2016-02-22 | Janssen Pharmaceutica Nv | PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES |
WO2009098061A1 (en) | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production |
AU2009247782C1 (en) * | 2008-05-13 | 2013-09-19 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline |
JP5539351B2 (en) * | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cyclohexyloxy-substituted heterocycles, medicaments containing these compounds, and methods for producing them |
CA2733159A1 (en) | 2008-08-08 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof |
EP2313377B1 (en) * | 2008-08-08 | 2016-01-06 | Boehringer Ingelheim International Gmbh | Method for stereoselective synthesis of bicyclic heterocycles |
CN101659658B (en) * | 2008-08-29 | 2014-04-02 | 北大方正集团有限公司 | Quinoline substituted by cyan |
CN101659657B (en) * | 2008-08-29 | 2014-05-14 | 北大方正集团有限公司 | Quinoline substituted by cyan and preparation method and applications thereof |
US8629153B2 (en) * | 2008-09-03 | 2014-01-14 | Boehringer Ingelheim International Gmbh | Use of quinazoline derivatives for the treatment of viral diseases |
SI2451445T1 (en) | 2009-07-06 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
CA2775601C (en) | 2009-09-28 | 2017-10-03 | Qilu Pharmaceutical Co., Ltd | 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors |
US20120046284A1 (en) * | 2010-02-15 | 2012-02-23 | Boehringer Ingelheim International Gmbh | Salts and hydrates of 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4--cyclohexan-1-yloxy)-7-methoxy-quinazoline, their use as a medicament and the preparation thereof |
CN102452988B (en) * | 2010-10-27 | 2016-01-27 | 中国科学院化学研究所 | A kind of quinazoline derivant and preparation method thereof |
EA023573B1 (en) | 2011-02-01 | 2016-06-30 | Бёрингер Ингельхайм Интернациональ Гмбх | 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diazaspiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof |
KR101317809B1 (en) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cell and non-metalic salt lubricant |
JP6105631B2 (en) | 2012-02-09 | 2017-03-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Stereoselective synthesis of 1,4-protected 9-hydroxy-5-oxo-1,4-diaza-spiro [5.5] undecane |
EP2752413B1 (en) | 2012-03-26 | 2016-03-23 | Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences | Quinazoline derivative and application thereof |
WO2014012859A1 (en) | 2012-07-19 | 2014-01-23 | Boehringer Ingelheim International Gmbh | Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof |
KR20140096571A (en) | 2013-01-28 | 2014-08-06 | 한미약품 주식회사 | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one |
KR101645112B1 (en) * | 2013-03-06 | 2016-08-02 | 아스트라제네카 아베 | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
TWI771327B (en) * | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | Novel compounds |
US11365189B2 (en) | 2019-04-25 | 2022-06-21 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of tyrosine kinase |
CN114867719A (en) | 2019-11-06 | 2022-08-05 | 柳韩洋行 | Pyrrolidine and piperidine compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
DE19911509A1 (en) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
GB9910577D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
DE10042058A1 (en) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
DE10042059A1 (en) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
-
2003
- 2003-03-25 EA EA200401191A patent/EA009300B1/en not_active IP Right Cessation
- 2003-03-25 IL IL16416703A patent/IL164167A0/en not_active IP Right Cessation
- 2003-03-25 KR KR1020047015565A patent/KR101064530B1/en not_active IP Right Cessation
- 2003-03-25 PL PL03371188A patent/PL371188A1/en unknown
- 2003-03-25 BR BR0308902-9A patent/BR0308902A/en not_active Expired - Fee Related
- 2003-03-25 AT AT03745271T patent/ATE557008T1/en active
- 2003-03-25 WO PCT/EP2003/003062 patent/WO2003082290A1/en active Application Filing
- 2003-03-25 EA EA200701302A patent/EA200701302A1/en unknown
- 2003-03-25 ME MEP-472/08A patent/MEP47208A/en unknown
- 2003-03-25 RS YUP-854/04A patent/RS85404A/en unknown
- 2003-03-25 CA CA2476008A patent/CA2476008C/en not_active Expired - Fee Related
- 2003-03-25 JP JP2003579827A patent/JP4776882B2/en not_active Expired - Fee Related
- 2003-03-25 AU AU2003226705A patent/AU2003226705B2/en not_active Ceased
- 2003-03-25 MX MXPA04009536A patent/MXPA04009536A/en active IP Right Grant
- 2003-03-25 CN CN038072424A patent/CN1642552B/en not_active Expired - Fee Related
- 2003-03-25 NZ NZ536114A patent/NZ536114A/en not_active IP Right Cessation
- 2003-03-25 EP EP03745271A patent/EP1492536B1/en not_active Expired - Lifetime
- 2003-03-27 UY UY27737A patent/UY27737A1/en not_active Application Discontinuation
- 2003-03-28 TW TW099102687A patent/TW201024269A/en unknown
- 2003-03-28 TW TW092107113A patent/TWI331604B/en not_active IP Right Cessation
- 2003-03-28 MY MYPI20031160A patent/MY127771A/en unknown
- 2003-03-28 AR ARP030101100A patent/AR039187A1/en not_active Suspension/Interruption
- 2003-03-28 PE PE2003000322A patent/PE20040169A1/en not_active Application Discontinuation
-
2004
- 2004-09-23 NO NO20043997A patent/NO329271B1/en not_active IP Right Cessation
- 2004-09-29 HR HR20040898A patent/HRP20040898A2/en not_active Application Discontinuation
-
2005
- 2005-12-02 HK HK05111036.8A patent/HK1079095A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PE20040169A1 (en) | 2004-05-24 |
NO329271B1 (en) | 2010-09-20 |
PL371188A1 (en) | 2005-06-13 |
EP1492536A1 (en) | 2005-01-05 |
KR101064530B1 (en) | 2011-09-14 |
ATE557008T1 (en) | 2012-05-15 |
CN1642552A (en) | 2005-07-20 |
NO20043997L (en) | 2004-10-27 |
TWI331604B (en) | 2010-10-11 |
EA200401191A1 (en) | 2005-04-28 |
EA200701302A1 (en) | 2007-12-28 |
AU2003226705A1 (en) | 2003-10-13 |
HK1079095A1 (en) | 2006-03-31 |
HRP20040898A2 (en) | 2005-10-31 |
IL164167A0 (en) | 2005-12-18 |
EA009300B1 (en) | 2007-12-28 |
WO2003082290A1 (en) | 2003-10-09 |
CA2476008C (en) | 2011-12-13 |
JP4776882B2 (en) | 2011-09-21 |
NZ536114A (en) | 2007-11-30 |
BR0308902A (en) | 2005-01-04 |
AR039187A1 (en) | 2005-02-09 |
KR20040094898A (en) | 2004-11-10 |
MY127771A (en) | 2006-12-29 |
CA2476008A1 (en) | 2003-10-09 |
TW201024269A (en) | 2010-07-01 |
TW200406211A (en) | 2004-05-01 |
MXPA04009536A (en) | 2005-01-25 |
RS85404A (en) | 2007-02-05 |
CN1642552B (en) | 2010-05-12 |
AU2003226705B2 (en) | 2008-11-06 |
EP1492536B1 (en) | 2012-05-09 |
JP2005529090A (en) | 2005-09-29 |
UY27737A1 (en) | 2003-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MEP47208A (en) | 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors | |
MEP59508A (en) | Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof | |
MEP58708A (en) | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof | |
MEP45608A (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them | |
MEP45508A (en) | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof | |
TW200730508A (en) | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | |
BG105765A (en) | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases | |
TW200505912A (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
WO2008078100A3 (en) | Tricyclic amine derivatives as protein tyrosine kinase inhibitors | |
WO2008148867A3 (en) | Quinoxaline derivatives as inhibitors of the tyrosine kinase activity of janus kinases | |
NO20065948L (en) | Quinazolin-4-yl-piperidine and cinnolin-4-yl-piperidine derivatives as PDE10 inhibitors for the treatment of CNS disorders | |
DE60332433D1 (en) | AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITOR | |
DE60332604D1 (en) | AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITOR | |
ATE371656T1 (en) | HETEROARYL-PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | |
MY150290A (en) | Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production | |
UY26902A1 (en) | BICYCLIC HETEROCYCLES, DRUGS CONTAINING THESE COMPOUNDS, THEIR EMPLOYMENT AND PROCEDURES FOR THEIR PREPARATION | |
TW200510341A (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
ATE386530T1 (en) | CHINAZOLINE DERIVATIVES AND THEIR USE IN CANCER TREATMENT | |
ATE412632T1 (en) | NEW ARYL-CONTAINING 5-ACYLINDOLINONES, THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS | |
MX2009007610A (en) | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof. | |
DE60023025D1 (en) | 3,4-DIHYDRO- (1H) CHINAZOLIN-2-ON COMPOUNDS AS CSBP / P39 KINASE INHIBITORS | |
DE60108626D1 (en) | USE OF 5-THIO, SULFINYL AND SULFONYLPYRAZOLO 3,4-B] PYRIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS | |
ECSP045330A (en) | BICYCLIC HETEROCICLES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURE FOR THEIR PREPARATION | |
ATE321572T1 (en) | COMBINED TUMOR THERAPY BASED ON SUBSTITUTED ACRYLOYL-DISTAMYCIN DERIVATIVES AND PROTEIN KINASE (SERINE/THREONINE KINASE) INHIBITORS | |
YU60501A (en) | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases |